Annenberg Oncology

On-line Courses

  • CME: Leukemia
    Acute Lymphoblastic Leukemia
    CME Credit: None
  • CME: Pancreatic Cancer
    Advances in the Management of Pancreatic Cancer
    CME Credit: None
  • CME: Leukemia
    Analysis of Recently Published Acute Lymphoblastic Leukemia Articles / Studies
    CME Credit: None
  • CME: Bladder Cancer
    ExpertPerspectives: Navigating Precision Medicine in Bladder Cancer: Optimizing the Identification and Selection of Patients for Immunotherapy
    CME Credit: None
  • CME: Leukemia
    Focus on Advancing Treatment for Acute Myeloid Leukemia
    CME Credit: None
  • CME: Lymphoma
    Advances in the Management and Treatment of Non-Hodgkin Lymphoma
    CME Credit: None
  • CME: Sarcoma
    New Treatments and a New Approach to Soft Tissue Sarcoma
    CME Credit: None
  • CME: Melanoma
    Melanoma: Updates from Brisbane, Australia
    CME Credit: None
  • CME: Prostate Cancer
    Optimizing Patient Outcomes in Castration-Resistant Prostate Cancer: Moving Urologists from Knowledge to Action
    CME Credit: None

Events

News and Perspectives

COVID-19: ASCO Patient Care Link

American Society of Clinical Oncology (ASCO) Patient Care Recommendations

Read more...
Added 3 months ago Web Resource

COVID-19: ASH Resources

American Society of Hematology (ASH) Resources

Read more...
Added 3 months ago Web Resource

COVID-19: NCCN Recommendations

National Comprehensive Cancer Network (NCCN) Recommendations

Read more...
Added 3 months ago Web Resource

COVID-19: ASCO Provider and Practice Link

American Society of Clinical Oncology (ASCO) Provider and Practice Recommendations

Read more...
Added 3 months ago Web Resource

Prostate Cancer: More positive data from TITAN trial

A double-blind, phase 3 TITAN trial, which randomly assigned patients with metastatic castration-sensitive prostate cancer to receive apalutamide or placebo, in addition to continuous androgen deprivation therapy (ADT), previously demonstrated significant improvement in radiographic progression-free survival (PFS) and overall survival in patients who received apalutamide (Chi KN, et al. N Engl J Med. 2019;381:13-24). At the 2020 Genitourinary Cancers Symposium, post hoc analysis data were presented which showed that addition of apalutamide to ADT also prolonged PFS2 (defined as the time from randomization to disease progression on 1st subsequent prostate cancer therapy or death, whichever occurred first) regardless of the type (hormonal or taxane) of the 1st subsequent life-prolonging therapy.

Read more...
Added 4 months ago Abstract

Multiple Myeloma: Positive ICARIA-MM Data Lead to Isatuximab FDA Approval

On March 2, 2020, FDA approved an anti-CD38 monoclonal antibody isatuximab in combination with pomalidomide and low-dose dexamethasone (Isa-Pd) for patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. This approval was based on the positive progression-free survival (PFS) data from a randomized, open-label, two-arm, phase 3 trial, ICARIA-MM; at a median follow-up of 11.6 months, median PFS was 11.5 months in the Isa-Pd arm versus 6.5 months in the Pd arm. Isatuximab represents an important new treatment option for patients with RRMM, especially those who are refractory to lenalidomide and a proteasome inhibitor.

Read more...
Added 4 months ago Article

Myeloma: Update from Orlando

Dr. Joseph Mikhael of the Translational Genomics Research Institute in Phoenix, Arizona, shares his perspective on new multiple myeloma data.

Added 5 months ago Video

Myeloma: Update from Orlando

Dr. Ola Landgren of Memorial Sloan Kettering Cancer Center in New York City, shares his perspective on new multiple myeloma data."

Added 5 months ago Video

PNCA: The Impact of Translational Science on Cancer

Dr. Linda Malkas of City of Hope presents the Grand Rounds lecture at Eisenhower Health where she talks about her journey toward identifying proliferating cell nuclear antigen (PCNA) as a potentially major player in cancer, and an early development of a small molecule inhibitor of a cancer-associated form of PCNA. She also discusses potential advantages of targeting molecular hubs, as opposed to targeting enzymatic activities, of cancer cells.

Added 5 months ago Video

Myeloma: Update from Orlando

Dr. Shaji Kumar of Mayo Clinic in Rochester, Minnesota, shares his perspective on new multiple myeloma data.

Added 6 months ago Audio

Prostate Cancer: Update from Chicago

Neal D. Shore, MD, reviews exciting new prostate cancer data.

Added 6 months ago Video

Bladder Cancer: Update from Chicago

Guru P. Sonpavde, MD, shares exciting new bladder cancer data.

Added 6 months ago Video

Lymphocytic Leukemia: Update from Chicago

Kanti R. Rai, MD, shares exciting new chronic lymphocytic leukemia data.

Added 6 months ago Video

Multiple Myeloma: Update from Chicago

Joseph Mikhael, MD, gives his perspective on new daratumumab data.

Added 7 months ago Video

Advance or Metastatic Urothelial Cancer: Update from Chicago

Daniel P. Petrylak, MD, gives an update on enfortumab vedotin EV-201 trial

Added 9 months ago Video